Verrica Pharmaceuticals stock forecast: up to 2.68 USD VRCA stock price prognosis
Forecast for Fri 20 Jan 2023 price
Verrica Pharmaceuticals stock price forecast for further price development up to 3.53% (time horizon: 1 day) and price target of 2.68 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) Verrica Pharmaceuticals share price prediction for 2023-01-20 with daily closed price projections
News <--> Close correlation for next day influence (-0.09)
Earnings per share
On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.
The forecast (dashed curve) of the share price performance is based on historical data.
Our forecast model is based on mathematical, statistical methods.
The website offers price forecasts and analysis tools for equities and other securities,
which are exclusively based on the prices of these securities in the past.
Information about these prices is provided to us by third parties. Although we believe,
If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and
correct sequencing of this information.
We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider
any financial data or other data of such issuers with the exception of the past prices of the securities.
Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or
that may be relevant for future security price flows. Investments require additional considerations.
Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor
or the tax implications an investment may have for the investor. Although we believe that
our mathematical models are a tool to try to explore the possibility for future price development
with the help of past performance, such developments are subject to a multitude of different influences.
and therefore not really predictable.
We cannot guarantee the success of any investment you make based on the information published here.
This website is for information purposes only. All information and data on this website cannot be guaranteed
to be accurate,
accuracy, completeness and appropriateness - neither explicit nor implicit.
Summerized Form 10-K with GPT-2
Both clinical trials evaluated the safety and efficacy of VP-102 compared to placebo. The FDA did not identify any clinical deficiencies. We resubmitted our NDA for VP-102 for the treatment of molluscum in December 2020. In addition, we are also developing VP-102 for the treatment of external genital warts. In July 2020, we received a CRL, from the FDA for our NDA. VP-102 was well-tolerated and no serious adverse events were reported. Safety and efficacy measures were evaluated every three weeks. Sixteen subjects were enrolled in this cohort and 12 completed the trial. In most cases, the submission of an NDA is subject to a substantial application user fee. The FDA may request additional information rather than accept an NDA for filing. The fourth certification described above is known as a paragraph IV certification. The term "remuneration" has been broadly interpreted to include anything of value. There remain judicial and Congressional challenges to certain aspects of the ACA. Other legislative changes have been proposed and adopted since the ACA was enacted. The address of the SEC\'s website is www.sec.gov. We have no products approved for commercialization and have never generated any revenue. We do not have sales or marketing infrastructure. In addition, our collaborators may not comply with these laws. In addition, there is a natural transition period when a new CRO commences work. We rely on our outside counsel to pay these fees. As of December 31, 2020, we had 29 full-time employees. Our stock price may be volatile. As a result, it may be difficult for you to sell shares at an attractive price or at all.
Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.
Meta analyst score 26.04/100
Not in ideal financial position.
Historical view, profit is growing.
Company revenue is not growing faster compared with the
Stock price is under book price value.
Institutional ownership list is based on filling form information
Bollinger Bollinger Bands for Verrica Pharmaceuticals can provide the information where the market is moving based on price information.
Verrica Pharmaceuticals Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.
On-Balance Volume information for Verrica Pharmaceuticals. On-Balance Volume information can be an indicator for bullish or bearish outcome.
Accumulation / Distribution (A/D) indicator information for Verrica Pharmaceuticals. The indicator identify divergences between price and volume flow.
Aroon Oscillator information for Verrica Pharmaceuticals. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.
Average Directional Index (ADX) information for Verrica Pharmaceuticals. The index can be used to identify the strengh of a trend.
Moving Average Convergence Divergence (MACD) for Verrica Pharmaceuticals. The indicator helps to predict trend direction and the momentum of the trend.
Stochastic Oscillator as momentum indicator for Verrica Pharmaceuticals. The indicator is useful for identifying overbought and oversold levels.
Relative Strength Index (RSI) for Verrica Pharmaceuticals. RSI is a momentum oscillator that measures the speed and change of price development.
The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period.
Primary usage of the indicator is to identify overbought or oversold signals.
When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30
Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio